Grants and Contributions:

Title:

Exploration of non-viral delivery of genetic material for immunotherapy for integration with microfluidics

Agreement Number:

973723

Agreement Value:

$100,000.00

Agreement Date:

Jul 1, 2021 - Jun 30, 2022

Description:

The goal of this project is to explore different non-viral technologies for precision targeting of gene therapies that could be deployed for different molecular targets and diseases. These include electroporation, lipid/liposomal nanoparticles, and cationic polymer nanoparticles. These methods will be tested for their suitability to integrate with immunotherapy, and one will be down-selected for value with microfluidics at the end of this project.

Organization:

National Research Council Canada

Expected Results:

In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.

Location:

Toronto, Ontario, CA M5S 1S8

Reference Number:

172-2021-2022-Q1-973723

Agreement Type:

Grant

Report Type:

Grants and Contributions

Recipient Business Number:

108162330

Recipient Type:

Academia

Recipient's Legal Name:

The Governing Council of the University of Toronto

Federal Riding Name:

University–Rosedale

Federal Riding Number:

35110

Program:

Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

Program Purpose:

Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.

NAICS Code:

541710 - R&D in the physical, engineering and life sciences